Advent Life Sciences
Showcasing the significance of two new funds
Amphista Therapeutics
Announcing the company’s Series A financing, leading to raised awareness with potential partners, investors and employees.
Amphista Therapeutics: Series B Financing
Announcing the company's Series B financing, which will be used to accelerate the growing pipeline of potent and selective bifunctional molecules and to extend its proprietary TPD platform.
AnaMar AB
Refreshing the company's corporate comms portfolio and strategy, including revamp of existing materials and supporting interest in lead asset ahead of BIO International Convention.
Anocca
Announcing the company's strategic collaboration with Shinobi Therapeutics to to develop allogeneic TCR-T cell therapies in oncology
AstraZeneca
Positioning the Company as a Partner of Choice as well as facilitating an Internal Change Management Programme.
BC Platforms
Positioning the company as a thought leader in precision medicine raising awareness with customers and investors.
ExeVir Bio EIB funding case study
Announcing the company's 25 million Euro financing from EIB to advance ExeVir’s COVID19 therapeutic
IRBM
Positioning the Company as a leading CDMO and highlighting their group Advaxia Biologics.
Medicxi
To launch Index’s new spin-out life sciences fund and publicise its first closing.
MitoRx Case Study: Promoting a published paper
Promoting R&D findings on small molecule mitochondrial modulators
Pneumagen
Raising visibility of its technology platform for the treatment for COVID-19 and supporting a new website and fundraising announcement.
Supporting with Organic & Paid Social Media
Supporting clients in raising their profile and facilitate engagement with key stakeholders through social media
TILT Biotherapeutics
Showcasing Phase 1 clinical trial data for TILT-123 combination therapy for platinum-resistant or refractory ovarian cancer, presented at AACR and ASCO.
TILT Biotherapeutics €22 Million Financing
Supporting TILT Biotherapeutics and their final close of €22 Million financing
Vaccitech
Support with corporate and investor materials and media relations supporting the partnership of its ChAdOx platform with AstraZeneca for a COVID-19 vaccine.
Vaccitech IPO
Coordinated a communications plan with key stakeholders to maximise visibility of Vaccitech's Series B financing and NASDAQ IPO listing
VaxEquity Strategic Collaboration with AstraZeneca
Announcing the company's strategic collaboration with AstraZeneca to Commercialise Self-Amplifying RNA platform
Advent Life Sciences
Showcasing the significance of two new funds
Amphista Therapeutics
Announcing the company’s Series A financing, leading to raised awareness with potential partners, investors and employees.
Amphista Therapeutics: Series B Financing
Announcing the company's Series B financing, which will be used to accelerate the growing pipeline of potent and selective bifunctional molecules and to extend its proprietary TPD platform.
AnaMar AB
Refreshing the company's corporate comms portfolio and strategy, including revamp of existing materials and supporting interest in lead asset ahead of BIO International Convention.
Anocca
Announcing the company's strategic collaboration with Shinobi Therapeutics to to develop allogeneic TCR-T cell therapies in oncology
AstraZeneca
Positioning the Company as a Partner of Choice as well as facilitating an Internal Change Management Programme.
BC Platforms
Positioning the company as a thought leader in precision medicine raising awareness with customers and investors.
ExeVir Bio EIB funding case study
Announcing the company's 25 million Euro financing from EIB to advance ExeVir’s COVID19 therapeutic
IRBM
Positioning the Company as a leading CDMO and highlighting their group Advaxia Biologics.
Medicxi
To launch Index’s new spin-out life sciences fund and publicise its first closing.
MitoRx Case Study: Promoting a published paper
Promoting R&D findings on small molecule mitochondrial modulators
Pneumagen
Raising visibility of its technology platform for the treatment for COVID-19 and supporting a new website and fundraising announcement.
Supporting with Organic & Paid Social Media
Supporting clients in raising their profile and facilitate engagement with key stakeholders through social media
TILT Biotherapeutics
Showcasing Phase 1 clinical trial data for TILT-123 combination therapy for platinum-resistant or refractory ovarian cancer, presented at AACR and ASCO.
TILT Biotherapeutics €22 Million Financing
Supporting TILT Biotherapeutics and their final close of €22 Million financing
Vaccitech
Support with corporate and investor materials and media relations supporting the partnership of its ChAdOx platform with AstraZeneca for a COVID-19 vaccine.
Vaccitech IPO
Coordinated a communications plan with key stakeholders to maximise visibility of Vaccitech's Series B financing and NASDAQ IPO listing
VaxEquity Strategic Collaboration with AstraZeneca
Announcing the company's strategic collaboration with AstraZeneca to Commercialise Self-Amplifying RNA platform